CGON vs GRVY vs IMVT vs RCUS vs IQV

For growth investors, CG Oncology, Inc.

Common stock (CGON) is the stronger pick with 254. 7% revenue growth year-over-year, versus -4. 3% for Arcus Biosciences, Inc. (RCUS). Gravity Co. , Ltd. (GRVY) offers the better valuation at 8. 9x trailing P/E, making it the more compelling value choice. Analysts rate CG Oncology, Inc. Common stock (CGON) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Gravity Co.

, Ltd. (GRVY) is the cheapest at 8. 9x versus IQVIA Holdings Inc. at 22. 8x.

Over the past 5 years, CG Oncology, Inc.

Common stock (CGON) delivered a total return of +86. 1%, compared to -44. 8% for Gravity Co. , Ltd. (GRVY). Over 10 years, the gap is even starker: GRVY returned +30. 2% versus RCUS's +45. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Gravity Co.

, Ltd. (GRVY) is the lower-risk stock at 0. 61β versus Arcus Biosciences, Inc. 's 1. 95β — meaning RCUS is approximately 222% more volatile than GRVY relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 2% for IQVIA Holdings Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), CG Oncology, Inc.

Common stock (CGON) is pulling ahead at 254. 7% versus -4. 3% for Arcus Biosciences, Inc. (RCUS). On earnings-per-share growth, the picture is similar: IQVIA Holdings Inc. grew EPS 4. 7% year-over-year, compared to -47. 5% for CG Oncology, Inc. Common stock. Over a 3-year CAGR, CGON leads at 176. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Gravity Co.

, Ltd. (GRVY) is the more profitable company, earning 12. 0% net margin versus -39. 9% for CG Oncology, Inc. Common stock — meaning it keeps 12. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GRVY leads at 14. 1% versus -47. 2% for CGON. At the gross margin level — before operating expenses — RCUS leads at 96. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for IMVT: 67.

2% to $45. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Gravity Co.

, Ltd. (GRVY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 61)). Arcus Biosciences, Inc. (RCUS) carries a higher beta of 1. 95 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (GRVY: +30. 2%, RCUS: +45. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (CGON (Healthcare) and GRVY (Technology) and IMVT (Healthcare) and RCUS (Healthcare) and IQV (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: CGON is a small-cap high-growth stock; GRVY is a small-cap deep-value stock; IMVT is a small-cap quality compounder stock; RCUS is a small-cap quality compounder stock; IQV is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.